Pletal (cilostazol) is a small molecule pharmaceutical. Cilostazol was first approved as Pletal on 1999-01-15. It is used to treat intermittent claudication, peripheral vascular diseases, and vascular graft occlusion in the USA. The pharmaceutical is active against cGMP-inhibited 3',5'-cyclic phosphodiesterase B. In addition, it is known to target cGMP-inhibited 3',5'-cyclic phosphodiesterase A.
|Indication||intermittent claudication, peripheral vascular diseases, vascular graft occlusion|